International Society for Mannosidosis and Related Diseases

Call Website

International Society for Mannosidosis and Related Diseases ISMRD is the leading advocate for families affected by a Glycoprotein Storage Disease. We are a US-based 501(c)(3) charity.

We seek to detect and cure these diseases, and to provide a global network of support and info for our families.

Save Your Spot for ISMRD's Virtual Scientific Conference on November 7, 2026! Join the International Society for Mannosi...
10/30/2026

Save Your Spot for ISMRD's Virtual Scientific Conference on November 7, 2026!

Join the International Society for Mannosidosis and Related Diseases (ISMRD) for our upcoming 2026 Virtual Conference, bringing together patients, families, clinicians, researchers, and industry partners from around the world.

This virtual event will be a day of learning, collaboration, and connection focused on advancing research and improving outcomes for individuals and families affected by glycoproteinoses.

✨ Topics will include:
🔬 Emerging therapies and translational science
🧬 Gene therapy and enzyme replacement therapy
📊 Natural history studies and long-term disease outcomes
🩺 Newborn screening for alpha-mannosidosis

Whether you’re living with a rare disease, caring for a loved one, conducting research, or working to advance treatments, we invite you to be part of the conversation!

📅 Register today: https://www.ismrd.org/wp-content/uploads/ISMRD_Virtual_Conference_2026.html

Together, we’re building a stronger community and advancing progress for the glycoproteinoses. 💙

A breakthrough finding in Mucolipidosis II and III research.Children living with Mucolipidosis II and III alpha/beta are...
08/23/2026

A breakthrough finding in Mucolipidosis II and III research.

Children living with Mucolipidosis II and III alpha/beta are missing a critical targeting enzyme that directs the cell’s waste-recycling enzymes to where they are needed. Without it, those enzymes are released into the blood instead of reaching the cells, allowing waste to accumulate and the disease to progress.

Today, there is no approved treatment for ML II or III.

But new research is giving our community reason to hope.

Dr. Patricia Dickson at Washington University in St. Louis and her research collaborators have engineered a redesigned version of the missing enzyme, known as S1-S3. Laboratory studies show that S1-S3 outperforms the natural protein it was designed to replace.

That is more than an encouraging result. It opens the door to a new approach for treating Mucolipidosis.

Now, we need to move this science forward.

ISMRD is working to raise $500,000 to fund three critical next steps:

1️⃣ Vector design optimization
Developing the system needed to package and deliver S1-S3.

2️⃣ Human cell testing
Determining whether the engineered enzyme performs as intended in human cells.

3️⃣ Dosing study
Testing delivery and dosing in our disease model, the critical step toward advancing the program toward human development.

Every dollar raised brings us closer to answering the questions that stand between the bench and the bedside.

Families living with Mucolipidosis ll and lll alpha/beta have waited long enough.

Help ISMRD turn science into therapy.

🔗 Visit our donation page and donate today! https://bit.ly/operation2stride

Together, we can help change what’s possible for ML families.

We’re incredibly grateful to Precise Painting & Drywall for sponsoring Operation Second Stride and helping us take anoth...
08/22/2026

We’re incredibly grateful to Precise Painting & Drywall for sponsoring Operation Second Stride and helping us take another step toward advancing research and a gene therapy for Mucolipidosis.

Based in the Raleigh-Durham area, Precise Painting & Drywall is the team to call when it’s time to transform a space. They bring quality craftsmanship, attention to detail, and pride in their work to every job.

And now, they’re helping us transform something even bigger: the future for people living with Mucolipidosis. ❤️

This September, we’re taking on 33 miles of the Appalachian Trail with a goal of raising $333,000 to advance research and gene therapy. Every sponsor, every donor, and every mile gets us closer to making that future possible.

We are incredibly grateful Precise Painting & Drywall for stepping up, supporting our mission, and showing what it means when a local business uses its platform to make a difference.

To get involved visit https://bit.ly/operation2stride

33 Miles, One Extraordinary Mission.ISMRD is proud to announce that PhRMA is sponsoring Operation Second Stride, as we t...
08/10/2026

33 Miles, One Extraordinary Mission.

ISMRD is proud to announce that PhRMA is sponsoring Operation Second Stride, as we take on 33 miles of the Appalachian Trail to raise $333,000 to advance gene therapy research for Mucolipidosis II/III alpha/beta.

PhRMA represents America’s leading biopharmaceutical research companies and works to advance policies that support the discovery and development of new medicines and innovative treatments.

We are grateful for PhRMA’s support of Operation Second Stride and their commitment to advancing innovation that can ultimately bring new hope to patients and families affected by rare diseases.

This September, we’ll carry that mission with us on the trail, honoring the resilience of families affected by Mucolipidosis and working toward a future where a diagnosis can come with hope for treatment.

Thank you to PhRMA for standing with ISMRD and helping us take another step toward a second future for families.

Learn more about PhRMA: https://www.phrma.org/

Learn more about Operation Second Stride: www.Operation2stride.org

ISMRD is hosting a Mucolipidosis II/III alpha/beta Roundtable at the National MPS Society 40th Annual Scientific & Famil...
07/31/2026

ISMRD is hosting a Mucolipidosis II/III alpha/beta Roundtable at the National MPS Society 40th Annual Scientific & Family Conference in Columbus, Ohio, on Sunday, August 2, from 10:00 a.m. to 2:00 p.m. ET.

As part of this important initiative, ISMRD is actively developing global clinical care consensus guidelines for Mucolipidosis II/III alpha/beta, and we greatly value the perspectives and experiences of patients and families. Your input will help shape recommendations that reflect the real-world needs of our community.

If you are unable to attend the conference in person, you are welcome to participate virtually via Zoom.

Please register using the link provided. https://app.smartsheet.com/b/form/019f9f1c016d7e939d69ca2134fea8b0?

We look forward to hearing your insights and working together to improve clinical care for individuals living with Mucolipidosis II/III alpha/beta.

OPERATION SECOND STRIDE is in full force! The International Society for Mannosidosis and Related Diseases (ISMRD) and Na...
07/24/2026

OPERATION SECOND STRIDE is in full force! The International Society for Mannosidosis and Related Diseases (ISMRD) and National MPS Society are coming together with a goal of fundraising $333,000 to advance research and development of a gene therapy for Mucolipidosis Alpha/Beta.

Beginning September 5, 2026, Jenny Jackson will be backpacking a 33-mile segment of the Appalachian Trail, marking a deeply personal milestone along the way. Every 11-mile marker will honor 11 years since her hip and pelvic reconstruction surgeries at UNC Orthopaedics - Chapel Hill, surgeries that changed the course of her life and mobility.

Living with Mucolipidosis meant years of pain, physical limitations, uncertainty, and relying on mobility aids just to get through daily life. There were moments when walking across a room felt overwhelming, let alone imagining backpacking through the mountains.

This journey is about resilience, advocacy, and pushing rare disease research forward for future generations. Every mile symbolizes resilience over perfection, and progress over limitation.

To learn more and get involved, visit Operation2stride.org

- Donations can be made directly through ⁠
https://www.ismrd.org/how-to-make-a-donation/

- Designate gifts to the “ML Challenge Grant”

- 100% of funds raised go directly to R&D.

If you are interested in sponsoring this event or even joining us on this hike, please reach out to [email protected].

The International MPS Symposium was a powerful reminder of what can happen when patients, families, researchers, clinici...
06/12/2026

The International MPS Symposium was a powerful reminder of what can happen when patients, families, researchers, clinicians, industry partners, and advocates come together with a shared purpose.

We’re excited to share several important updates from ISMRD:

🧡 We officially launched our Alpha-Mannosidosis Newborn Screening Initiative and have identified a dedicated steering committee to help move this critical effort forward.

🩵 JCR has launched a Fucosidosis multi-center Natural History Study to better understand disease progression and support future therapeutic development.

🧡 Operation Second Stride is underway, mobilizing supporters and raising vital funds to advance the development of a gene therapy for Mucolipidosis. Every dollar raised helps move this promising program closer to the clinic.

🩵 Early planning is underway for a Mucolipidosis Roundtable, bringing together key stakeholders to prepare for clinical readiness

🧡 The Galactosialidosis and Sialidosis Natural History Studies at the NIH are actively enrolling participants.

🩵 Discussions surrounding patient registries, natural history data, and meaningful clinical outcome measures remain at the forefront as we work to prepare our community for future clinical trials.

While there is still much work to be done, the momentum across the ISMRD community continues to grow. Thank you to everyone who contributes their time, expertise, and passion to advancing research and improving the lives of individuals living with glycoprotein storage diseases.

Together, we are moving forward.

Today, on International Mucolipidosis Awareness Day, we come together to raise awareness, support families, and shine a ...
05/15/2026

Today, on International Mucolipidosis Awareness Day, we come together to raise awareness, support families, and shine a light on those living with Mucolipidosis.

Behind every diagnosis is a story of strength, resilience, courage, and unconditional love. While Mucolipidosis may be rare, the voices of this community matter deeply and deserve to be heard.

Awareness helps drive research, advocacy, earlier diagnosis, better treatments, and hope for the future.

Today we honor every warrior, caregiver, advocate, researcher, and loved one affected by Mucolipidosis. Your strength inspires us all.

Please help spread awareness by sharing this post and learning more about rare diseases. Together, we can make a difference.

Two fierce advocates, Sam Jamil and Shirley Jamil, wrote a play titled Ward 76, inspired by Sam’s experiences growing up...
05/13/2026

Two fierce advocates, Sam Jamil and Shirley Jamil, wrote a play titled Ward 76, inspired by Sam’s experiences growing up in the hospital.

The play explores conversations around rare diseases, particularly Mucolipidosis type III, alongside themes of friendship, loneliness, resilience, and identity. There’s also a touch of toilet humour and a subtle thread of mild horror woven throughout.

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

In collaboration with the National MPS Society and the generous support of our community, we secured $25,000 to continue...
04/25/2026

In collaboration with the National MPS Society and the generous support of our community, we secured $25,000 to continue advancing the gene therapy program to treat Mucolipidosis at WashU.

Let’s keep the momentum going! Every dollar raised goes towards advancing this critical research.

Our goal is to raise $500,000 to fully support this initiative. 🧡🩵🧡 We’ve never been closer to a therapy than we are today.

Please consider donating and designate your donation to the ML Challenge Grant: Ismrd.org/how-to-make-a-donation/

Address

P. O. Box 683
Blackwood, NJ
08012

Alerts

Be the first to know and let us send you an email when International Society for Mannosidosis and Related Diseases posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share